English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Poster

Low power Z-spectrum analysis for isolated NOE and amide CEST-MRI at 3T with comparison to 9.4T

MPS-Authors
/persons/resource/persons215996

Deshmane,  A
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;
Max Planck Institute for Biological Cybernetics, Max Planck Society;

/persons/resource/persons214560

Zaiss,  M
Max Planck Institute for Biological Cybernetics, Max Planck Society;
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;

/persons/resource/persons216025

Herz,  K
Max Planck Institute for Biological Cybernetics, Max Planck Society;
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;

/persons/resource/persons84187

Scheffler,  K
Max Planck Institute for Biological Cybernetics, Max Planck Society;
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;

External Resource

Link
(Abstract)

https://www.ismrm.org/18/Traditional_Posters.pdf
(Abstract)

Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Deshmane, A., Zaiss, M., Bender, B., Lindig, T., Windschuh, J., Herz, K., et al. (2018). Low power Z-spectrum analysis for isolated NOE and amide CEST-MRI at 3T with comparison to 9.4T. Poster presented at Joint Annual Meeting ISMRM-ESMRMB 2018, Paris, France.


Cite as: https://hdl.handle.net/21.11116/0000-0001-7D80-2
Abstract
A snapCEST sequence was optimized for imaging of protein CEST effects at 3T with low saturation power. Full Z-spectrum sampling allows Lorentzian fitting of amide, NOE, semisolid MT, and water pools. Validation against data acquired at 9.4T demonstrates effective labeling of selective amide and NOE CEST effects at 3T. Data acquired in a brain tumor patients demonstrates clinical feasibility.